Nordic Capital & Permira to Acquire Bavarian Nordic
Nordic Capital and Permira to Acquire Bavarian Nordic in $2.8B Deal Bavarian Nordic, a key player in the vaccine...
No videos found.
Clearmind Medicine Starts Phase I/IIA Trial of CMND-100 for Alcohol Use Disorder
Clearmind Medicine has initiated a new clinical trial site at Tel Aviv Sourasky Medical Center (TASMC) for its Phase...
Regen Biopharma Seeks Orphan Drug Designation for Lead Product
Regen Biopharma’s pursuit of an orphan drug designation for Hemaxellerate, its stem cell-derived therapy for aplastic anemia, marks a...
Respiree Closes $11.6M Series A Financing Round
Respiree Secures $11.6M Series A to Expand AI-Powered Patient Monitoring Platform Respiree, a health tech company focused on AI-driven...
Roche’s Strong Momentum: 7% Growth in H1 2025
Roche Reports Robust H1 2025 Performance Driven by Pharmaceutical Growth Roche has announced strong financial results for the first...
Pfizer, BioNTech Get CHMP Nod for Adapted COVID-19 Vaccine in EU
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for Pfizer...
Sarclisa Approved in EU for Newly Diagnosed Multiple Myeloma
Sanofi secures expanded EU approval for Sarclisa in newly diagnosed multiple myeloma, bolstering its presence in the competitive myeloma...
Rakovina Therapeutics Enhances Warrant Program
Rakovina Therapeutics is incentivizing early warrant exercises in a move to bolster its cash position and potentially streamline its...
Cabometyx® Approved in EU for Advanced Neuroendocrine Tumors
Cabometyx Secures Broad EU Approval for Neuroendocrine Tumors, Reshaping the Treatment Landscape Ipsen’s cabozantinib (Cabometyx) has received European Commission...
Alterity Therapeutics Publishes Novel MRI Endpoint Data
Alterity Therapeutics’ recently published research in the •Annals of Clinical and Translational Neurology• highlights a significant advancement in Multiple...